- Home
- GCTK vs REVB Comparison
GCTK vs REVB Comparison
Compare GCTK & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- REVB
- Stock Information
- Founded
- GCTK 2001
- REVB 2020
- Country
- GCTK United States
- REVB United States
- Employees
- GCTK N/A
- REVB N/A
- Industry
- GCTK Medical/Dental Instruments
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- REVB Health Care
- Exchange
- GCTK Nasdaq
- REVB Nasdaq
- Market Cap
- GCTK 3.7M
- REVB 3.8M
- IPO Year
- GCTK N/A
- REVB N/A
- Fundamental
- Price
- GCTK $5.60
- REVB $2.72
- Analyst Decision
- GCTK
- REVB
- Analyst Count
- GCTK 0
- REVB 0
- Target Price
- GCTK N/A
- REVB N/A
- AVG Volume (30 Days)
- GCTK 1.6M
- REVB 213.6K
- Earning Date
- GCTK 08-12-2025
- REVB 08-08-2025
- Dividend Yield
- GCTK N/A
- REVB N/A
- EPS Growth
- GCTK N/A
- REVB N/A
- EPS
- GCTK N/A
- REVB N/A
- Revenue
- GCTK N/A
- REVB N/A
- Revenue This Year
- GCTK N/A
- REVB N/A
- Revenue Next Year
- GCTK N/A
- REVB N/A
- P/E Ratio
- GCTK N/A
- REVB N/A
- Revenue Growth
- GCTK N/A
- REVB N/A
- 52 Week Low
- GCTK $5.16
- REVB $2.11
- 52 Week High
- GCTK $3,756.00
- REVB $168.00
- Technical
- Relative Strength Index (RSI)
- GCTK 40.61
- REVB 42.83
- Support Level
- GCTK $5.61
- REVB $2.20
- Resistance Level
- GCTK $7.38
- REVB $2.92
- Average True Range (ATR)
- GCTK 1.25
- REVB 0.27
- MACD
- GCTK 0.04
- REVB 0.24
- Stochastic Oscillator
- GCTK 4.40
- REVB 86.40
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).